Log in to search using one of your social media accounts:

 

Pixium Vision wins French approval for Prima sub-retinal implant study
Pixium Vision (EPA:PIX) said today it won approval from France’s regulatory agency to launch a feasibility clinical study of its next-gen Prima sub-retinal implant in patients with advanced dry age-related macular degeneration. The Prima system is a next-gen wireless implant with a micro photovoltaic chip designed to be implanted under the retina to convert pulsed near-infra-red invisible light received from external glasses with an integrated mini-camera into electrical signals transmitted to the brain through the optic nerve, the company said. The system is designed to treat retinal dystrophies with a foc...
Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Pixium Vision Source Type: news

Second Sight wins go-ahead for German Argus II study in better-sighted RP patients
This study has the potential to change the management of patients with RP and, if successful, greatly expand the patient population who can benefit from this treatment, and for whom the Argus II could be a solution,” Dr. Walter of Germany’s Universitätsklinikum Aachen said in a prepared statement. In July, Second Sight said its Argus II retinal prosthesis system won expanded reimbursement coverage from the Centers for Medicare and Medicaid Services in 11 additional states and the District of Columbia. See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif. The post...
Source: Mass Device - October 17, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Regulatory/Compliance Second Sight Source Type: news

Single gene injected into eye reverses type of blindness
Breakthrough made by Oxford researchers in treating retinitis pigmentosa, which affects 20,000 Britons. A single gene injected into the back of the eye was found to restore vision. (Source: the Mail online | Health)
Source: the Mail online | Health - October 2, 2017 Category: Consumer Health News Source Type: news

Keeping Calm in the OR: Ophthalmology Times
(MedPage Today) -- Also, approaches to promote cone regeneration in retinitis pigmentosa (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 19, 2017 Category: American Health Source Type: news

Second Sight Medical enters Russian market
Second Sight Medical (NSDQ:EYES) said today it entered the Russian market, with the 1st patient treated with its Argus II Retinal Prosthesis System in Moscow. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the Sylmar, Calif.-based company said. The 1st implant was performed at the Federal State Institution & Clinical Research Center of the Federal Medico-Biological Agency at the end of June 2017 by a team of surgeons, with Dr. Paulo Stanga ...
Source: Mass Device - July 26, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic second-sight-medical Source Type: news

Second Sight Medical wins expanded CMS coverage for Argus II
Second Sight Medical (NSDQ:EYES) said today its Argus II retinal prosthesis system won expanded reimbursement coverage from the Centers for Medicare and Medicaid Services in 11 additional states and the District of Columbia. With the expansion, the Sylmar, Calif.-based company said it’s Argus II device is now reimbursable in 7 of the 12 Medicare Administrative Contractor jurisdictions, covering the device in a total of 28 states, 2 territories and D.C. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulse...
Source: Mass Device - July 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic second-sight-medical Source Type: news

Gene mutation linked to retinitis pigmentosa in Southwestern US Hispanic families
(University of Texas Health Science Center at Houston) Thirty-six percent of Hispanic families in the U.S. with a common form of retinitis pigmentosa got the disease because they carry a mutation of the arrestin-1 gene, according to a new study from researchers at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 26, 2017 Category: International Medicine & Public Health Source Type: news

Boston man's bionic eye gives back sight to blind man
Anthony Andreottola, 56, was diagnosed with retinitis pigmentosa and was blind at 35 years old. The Boston man was finally able to see again with the help of a bionic eye surgery in 2015. (Source: the Mail online | Health)
Source: the Mail online | Health - June 16, 2017 Category: Consumer Health News Source Type: news

Bionic eye helps blind man see with "artificial vision"
A Boston man who lost his sight to the eye disease retinitis pigmentosa is getting a new look at the world with bionic eye technology. Paula Ebben of CBS Boston station WBZ reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 14, 2017 Category: Consumer Health News Source Type: news

Medford Man Receives Bionic Eye
MEDFORD (CBS) — After 20 years of darkness, there is light. It seems like science fiction, but a bionic eye implant is bringing a kind of sight to the blind. It’s not what you and I see, but for a small number of people, it’s making all the difference. “It’s not actual vision. It’s what they call artificial vision,” says Anthony Andreotolla, one of the first people to ever receive a bionic eye. Every day he puts on his gear, leaves his Medford home and rides the MBTA to his job in Downtown Crossing. Anthony Andreotolla wearing bionic eye (WBZ-TV) Andreotolla has retinitis pigm...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 13, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Seen On WBZ-TV Syndicated Local Bionic Eye Medford Paula Ebben Second Sight Source Type: news

Oxford robotic surgery, synthetic retina advances could help visually impaired
[Image from unsplash.com]The University of Oxford has recently had some major advances for treating the visually impaired. Surgeons at the university recently performed the world’s first operation inside the eye using robotics and a student created what the university says is the first synthetic retina. Ophthalmology professor Robert MacLaren and Nuffield Medical fellow Dr. Thomas Edwards performed eye surgery using a remotely controlled robot, lifting a membrane of the retina at the back right of the eye that was 1/100 mm thick. The surgery was performed on the Rev. Dr. William Beaver. Beaver’s surgery was per...
Source: Mass Device - May 12, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Clinical Trials Optical/Ophthalmic Research & Development blindness MedTech retinitis pigmentosa Robotic Surgery Source Type: news

Student Creates First Synthetic Retina For Visually Impaired
Study could revolutionise bionic implant industry and development of less invasive technologies helping to treat degenerative eye conditions such as retinitis pigmentosa (Source: Disabled World)
Source: Disabled World - May 5, 2017 Category: Disability Tags: Visual Aid Products and Information Source Type: news

Second Sight shares drop on Q1 miss
Shares in Second Sight Medical (NSDQ:EYES) have dropped today after the medical device maker missed expectations on Wall Street with its 1st quarter results. The Sylmar, Calif-based company posted losses of $7.5 million, or 16¢ per share, on sales of $1 million for the 3 months ended March 31, seeing losses grow 29.8% while sales shrunk 4.2% compared with the same period during the prior year. Analysts on Wall Street were expecting to see losses per share of 14¢, which Second Sight medical came in just above. “With a focus on execution and our centers of excellence strategy, we had strong implant volume dur...
Source: Mass Device - May 4, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup second-sight-medical Source Type: news

Using CRISPR to reverse retinitis pigmentosa and restore visual function
Using the gene-editing tool CRISPR/Cas9, researchers have reprogrammed mutated rod photoreceptors to become functioning cone photoreceptors, reversing cellular degeneration and restoring visual function in two mouse models of retinitis pigmentosa. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 21, 2017 Category: Science Source Type: news

Using CRISPR to reverse retinitis pigmentosa and restore visual function
(University of California - San Diego) Using the gene-editing tool CRISPR/Cas9, researchers at University of California San Diego School of Medicine and Shiley Eye Institute at UC San Diego Health, with colleagues in China, have reprogrammed mutated rod photoreceptors to become functioning cone photoreceptors, reversing cellular degeneration and restoring visual function in two mouse models of retinitis pigmentosa. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 21, 2017 Category: Biology Source Type: news

7 medtech stories we missed this week: April 14, 2017
[Image from unsplash.com]From FDA approvals to business expansion plans, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. BioTelemetry launches offer to acquire LifeWatch BioTelemetry and LifeWatch announced in an April 9 press release that the 2 companies have entered a transaction agreement that states BioTelemetry will launch a tender offer to acquire all shares of LifeWatch. The LifeWatch shareholders will receive either 10 Swiss francs in cash and 0.1457 shares of BioTelemetry stock per LifeWatch share or 8 Swiss francs in cash and 0.2175 shares of BioTelemetry stock per ...
Source: Mass Device - April 14, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Clinical Trials Food & Drug Administration (FDA) Regulatory/Compliance Research & Development Acelity BioTelemetry CollPlant LifeWatch MedTech Second Sight Sight Science Toshiba Medical Source Type: news

Terumo taps DeRyke as CV CEO | Personnel Moves – April 7, 2017
Terumo Corp. (TYO:4543) said yesterday it tapped Rob DeRyke as its new CV group prez & CEO, effective April 1, 2017, succeeding a retiring Mark Sutter. Prior to his appointment, DeRyke operated as Terumo CV group electromechanical systems division prez, the company said. “Under his leadership, Rob brought stability and improved profitability to the business,” Terumo Corp prez & CEO Shinjiro Sato said in a press release. DeRyke joined Terumo in 2012 as corporate quality VP, and has 25 years of experience in med device and pharmaceuticals, the company said. He has previously held positions at Ba...
Source: Mass Device - April 7, 2017 Category: Medical Equipment Authors: MassDevice staff Tags: Business/Financial News Active Implants AdvaMed Alphatec Holdings Inc. Anika Therapeutics Inc. Apollo Endosurgery Aurora Spine Baxter Biocorp Biogen Idec Biolase Technology Inc Bioventus LLC Bonesupport Clal Biotech Delcath Sys Source Type: news

Chinese backers put $18m into Bionic Vision Technologies
A pair of Chinese backers put $18 million into Bionic Vision Technologies and its retinal implant for blindness, the Australian company said today. Hong Kong-based China Huarong International Holdings and State Path Capital ponied up A$23.5 million, BVT said, noting that it plans to use the cash to build devices and launch clinical trials in retinitis pigmentosa, based on a 3-patient study using a prototype. The company developed the device using A$50 million (about $38.3 million) from a 5-year Special Research Initiative grant via the Australian Research Council. Existing backers include the Unive...
Source: Mass Device - April 3, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Optical/Ophthalmic Wall Street Beat Bionic Vision Technologies Source Type: news

Is this artificial retina implant going to restore vision for millions of people?
(Natural News) Retinitis pigmentosa refers to a group of conditions in which the photoreceptors of the retina and the pigment epithelium under the photoreceptors are damaged. The condition is progressive and often runs in families. It is also the leading cause of blindness specifically caused by retinal degeneration. Vision problems usually start revealing themselves in... (Source: NaturalNews.com)
Source: NaturalNews.com - March 25, 2017 Category: Consumer Health News Source Type: news

6 visual impairment breakthroughs you need to know
[Image courtesy unsplash.com]About 285 million people have some form of visual impairment in the world, according to the World Health Organization. Of that number, 39 million are considered blind, and 246 million have low vision. Three-fifths of all vision impairment can be prevented or cured. Uncorrected refractive errors are one of the main causes of vision impairment in the world. There has been a host of recent breakthroughs, however, that offer hope for the visually impaired. There’s a smart watch that relays smartphone notifications using braille and retinal prosthetics that could restore sight. Here ...
Source: Mass Device - March 22, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Biotech Clinical Trials Implants Optical/Ophthalmic Prosthetics Research & Development blindness eSight Corporation gene therapy Keratonconus MedTech Nanovision Biosciences retinitis pigmentosa University of California San Diego Source Type: news

Genetic engineering prevents retinal cell loss in mice
Silencing a gene called Nrl in mice slowed degenerative diseases of the retina. The findings could lead to ways to prevent vision loss from diseases such as retinitis pigmentosa. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - March 20, 2017 Category: Consumer Health News Source Type: news

NightstaRx initiates Phase I/II trial of AAV-XLRPGR therapy to treat XLRP
UK-based biopharmaceutical company NightstaRx (Nightstar) has initiated enrolment and dosing in a Phase I/II clinical trial of its gene therapy 'AAV- XLRPGR' for the treatment of patients with X-linked retinitis pigmentosa (XLRP). (Source: Drug Development Technology)
Source: Drug Development Technology - March 20, 2017 Category: Pharmaceuticals Source Type: news

NIH scientists deploy CRISPR to preserve photoreceptors in mice
Silencing a gene calledNrlin mice prevents the loss of cells from degenerative diseases of the retina, according to a new study. The findings could lead to novel therapies for preventing vision loss from human diseases such as retinitis pigmentosa. The study was conducted by researchers at the National Eye Institute (NEI), part of the National Institutes of Health, and was published online today in Nature Communications.     (Source: News from NEI)
Source: News from NEI - March 14, 2017 Category: Opthalmology Authors: balintfyj Source Type: news

Volker Busskamp receives prize for application-oriented neurobiological research
(Goethe University Frankfurt) The young researcher has been awarded for his contribution to a gene therapy approach to treat retinitis pigmentosa and for the development of artificial neuronal circuits. Retinitis pigmentosa is an inherited eye disease that leads to blindness. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 14, 2017 Category: Biology Source Type: news

Breast cancer drug dampens immune response, protecting light-sensing cells of the eye
The breast cancer drug tamoxifen appears to protect light-sensitive cells in the eye from degeneration, according to a new study in mice. The drug prevented immune cells from removing injured photoreceptors, the light-sensitive cells of the retina in the back of the eye. The study, recently reported in theJournal of Neuroscience, suggests tamoxifen might work for the treatment of age-related macular degeneration (AMD) and retinitis pigmentosa (RP), blinding diseases that lack good treatment options. (Source: News from NEI)
Source: News from NEI - March 13, 2017 Category: Opthalmology Authors: balintfyj Source Type: news

Second Sight Medical  closes $20m rights offering
Second Sight Medical (NSDQ:EYES) said today it closed a previously announced rights offering, retaining approximately $20.1 million with proceeds slated to support development and improvement of its Argus II retinal prosthesis. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said. In the oversubscribed round, Sylmar, Calif.-based offered non-transferable subscription rights to purchase units composed of a share of Second Sight common...
Source: Mass Device - March 9, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news

7 medtech stories we missed: Feb. 17, 2017
[Image from unsplash.com]Several companies released diabetes study results this week, while companies like BioTime closed on their public offerings and Pixium implanted its first bionic eye. Here are 7 medtech stories we missed this week, but were still worth mentioning. 1. Insulet touts glucose control study Insulet Corp. announced the results from its first feasibility study of its Omnipod Horizon hybrid closed-loop system in a Feb. 17 news release. The positive results showed that the glucose control algorithm performed well and was safe to used day and night for adults who have type 1 diabetes. It also s...
Source: Mass Device - February 17, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Business/Financial News Diabetes Food & Drug Administration (FDA) BioTime FlowAid Medical Technologies Insulet Corporation Medtronic Pixium Vision Polyganics Tandem Diabetes Care Valeritas Holdings Source Type: news

Pixium logs German reimbursement win for Iris II ‘ bionic eye ’
Pixium Vision (EPA:PIX) said today that its Iris II ‘bionic eye’ won NUB 1 reimbursement status from the German Institute for the Hospital Remuneration System. The company’s epi-retinal implant has 150 electrodes and a bio-inspired camera intended for patients who have lost sight due to retinitis pigmentosa. A computer processes images captured by the camera and transmits the data into a signal, which is then transferred back and projected onto an intraocular implant. The incoming signal stimulates the optic nerve and generates images that the brain can interpret as visual signals. This status i...
Source: Mass Device - February 14, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Implants Optical/Ophthalmic Prosthetics Wall Street Beat Pixium Vision Source Type: news

Second Sight announces upcoming rights offering
Second Sight Medical (NSDQ:EYES) today released information on an upcoming rights offering, with plans to open on February 10, with proceeds slated to support development and improvement of its Argus II retinal prosthesis. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said. In the round, Sylmar, Calif.-based will offer non-transferable subscription rights to purchase units composed of a share of Second Sight common stock and a 5-ye...
Source: Mass Device - February 6, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news

Second Sight wins German reimbursement for Argus II retinal prosthesis
Second Sight Medical (NSDQ:EYES) said today it won reimbursement coverage for its Argus II epiretinal prosthesis from the German Institute for the Hospital Renumeration System, covering 15 hospitals in the group’s NUB1 innovation program. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said. The decision will allow approved hospitals to negotiate reimbursement for treating patients with advanced stage retinitis pigmentosa ...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news

Second Sight Medical wins U.K. reimbursement nod for Argus II ‘ bionic eye ’
Second Sight Medical (NSDQ:EYES) said today that the U.K.’s National Health Service granted reimbursement for the company’s Argus II retinal prosthesis system for blind patients with retinitis pigmentosa. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said. The U.K.’s NHS said that “a selective group of severely blind patients with Retinits Pigementosa can have access to the Argus II,” according to Second Si...
Source: Mass Device - December 22, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news

NHS to fund pioneering bionic eye surgery
Electronic implants will restore some vision to patients with retinitis pigmentosa, an inherited eye disease (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 22, 2016 Category: Pharmaceuticals Source Type: news

MassDevice.com +5 | The top 5 medtech stories for November 7, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. First patient receives Pixium bionic vision implant Pixium Vision said today that the 1st patient in the UK was implanted with its IRIS II bionic vision system. The epi-retinal implant has 150 electrodes and a bio-inspired came...
Source: Mass Device - November 7, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

First patient receives Pixium bionic vision implant
Pixium Vision (EPA:PIX) said today that the 1st patient in the UK was implanted with its IRIS II bionic vision system. The epi-retinal implant has 150 electrodes and a bio-inspired camera intended for patients who have lost sight due to retinitis pigmentosa. The French company said the implantation and activation was performed in September by principal investigator Dr. Mahi Muqit at Moorfields Eye Hospital. The procedure was done as a part of Pixium’s ongoing, multi-center clinical trial to evaluate the efficacy of IRIS II as a treatment to compensate for blindness and provide greater autonomy for patients. &ldq...
Source: Mass Device - November 7, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Implants Neuromodulation/Neurostimulation Optical/Ophthalmic Pixium Vision Source Type: news

Second Sight wins CMS reimbursement codes for Argus II ‘ bionic eye ’
Second Sight Medical (NSDQ:EYES) said today it won reimbursement coverage from the Centers for Medicare & Medicaid Services for procedures using its Argus II retinal prosthesis system designed to restore some vision to blind patients. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said. Sylmar, Calif.-based Second Sight Medical said that surgical procedures which include its Argus II will now receive $150,000 from CMS ...
Source: Mass Device - November 2, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news

Fuji ’ s Cellular Dynamics launches retinal disease-focused Opsis Therapeutics
Fujifilm Holdings (TSE:4901) company Cellular Dynamics International said today it is launching Opsis Therapeutics, a new venture aiming to develop treatments for patient suffering from retinal diseases. The newly formed business aims to focus on retinal cell manufacturing and application of regenerative medicines for treating retinal diseases, the company said. CDI made the initial seed investment in Opsis Therapeutics with additional investments slated “as needed” for full-scale development. “Acquired and inherited diseases of the retina, such as age-related macular degeneration and retinitis pigme...
Source: Mass Device - September 28, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Regenerative Medicine Cellular Dynamics International Inc. Fujifilm Holdings Opsis Therapeutics Source Type: news

Researchers identify treatment target for blinding diseases
A common pathway involved in photoreceptor death has been identified in retinitis pigmentosa, advanced dry age-related macular degeneration and other retinal diseases, with early evidence of a possible halt to vision loss related to treatment of the pathway. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 28, 2016 Category: Science Source Type: news

Pixium Vision wins CE Mark for Iris II retinal prosthesis
French retinal implant maker Pixium Vision said Monday it won CE Mark approval in the European Union for its Iris II bionic vision system designed for individuals with vision loss from outer retinal degeneration. The Iris system is comprised of a retinal implant and a pair of camera-mounted glasses connected to a “pocket computer.” The computer processes images captured by the glasses and transmits the data into a signal that’s transferred back and projected onto the intraocular implant, where it stimulates the optic nerve and generates images that the brain learns to interpret as visual signals...
Source: Mass Device - July 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Optical/Ophthalmic Regulatory/Compliance Pixium Vision Source Type: news

Stem Cell Partnership: Patient Advocates And Scientists At The International Society For Stem Cell Research Convention
STEM CELL PARTNERSHIP: Patient Advocates and Scientists at the International Society for Stem Cell Research Convention By Don C. Reed This year's International Society for Stem Cell Researchers (ISSCR) conference was enormous, three vast floors of San Francisco's magnificent Moscone West convention center. As a watering hole brings animals together, the ISSCR concentrates the world's top stem cell scientists. From around the world they came, four thousand of them this year, representing almost sixty countries. Interspersed with them were patients and patient advocates, those who would benefit most from scientific ad...
Source: Science - The Huffington Post - July 8, 2016 Category: Science Source Type: news

Second Sight reels in $19m from oversubscribed rights offering
Second Sight Medical (NSDQ:EYES) said today it raised $19.8 million from an oversubscribed round of rights offering to shareholders of record, with funds slated to support a post-market study of its Argus II retinal prosthesis system. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said. Sylmar, Calif.-based Second Sight Medical will float approximately 6 million shares of stock at $3.31 per share, equal to 85% of the closing pr...
Source: Mass Device - June 1, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news

Pixium wins UK nod for Iris II ‘bionic eye’ trial
French retinal implant maker Pixium Vision said today it won U.K. Medicines & Healthcare products Regulatory Agency approval to initiate a clinical trial of its Iris II bionic vision system designed to restore sight to patients with retinitis pigmentosa. The Iris system is comprised of a retinal implant and a pair of camera-mounted glasses connected to a “pocket computer.” The computer processes images captured by the glasses and transmits the data into a signal that’s transferred back and projected onto the intraocular implant, where it stimulates the optic nerve and generates images that t...
Source: Mass Device - May 31, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Pixium Vision Source Type: news

US researchers investigate gene therapy treatment for X-linked retinitis pigmentosa
Researchers from the University of Pennsylvania have revealed a new animal study data, which analyses the efficacy of an investigational, adeno-associated virus (AAV) vector gene therapy treatment for X-linked retinitis pigmentosa (XLRP). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 2, 2016 Category: Pharmaceuticals Source Type: news

QLT ends enrolment for natural history study in patients with RP and LCA
Canadian-based biotechnology company QLT has completed enrolment in its natural history study in subjects with Inherited Retinal Disease (IRD), phenotypically diagnosed with Retinitis Pigmentosa (RP), or Leber Congenital Amaurosis (LCA), due to under… (Source: Drug Development Technology)
Source: Drug Development Technology - April 24, 2016 Category: Pharmaceuticals Source Type: news

MassDevice.com +5 | The top 5 medtech stories for March 30, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Trinity Medical picks up CasMed’s neonate disposables for $3m Trinity Medical Devices said yesterday that it paid $3.35 million for CAS Medical System‘s line of neonatal intensive care disposables. The deal includes...
Source: Mass Device - March 30, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Retina Implant Secures CE Mark for Wireless Subretinal Implant
CE certification enables commercialisation of Alpha AMS device to restore some useful vision in patients blinded by retinitis pigmentosa REUTLINGEN, Germany, March 30, 2016 -- (Healthcare Sales & Marketing Network) -- Retina Implant AG, the leading dev... Devices, Ophthalmology, RegulatoryRetina Implant AG, Alpha AMS, Subretinal Implant, retinal implant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 30, 2016 Category: Pharmaceuticals Source Type: news

Retina Implant wins CE Mark for next-gen blindness implant
Retina Implant said today that it won CE Mark approval in the European Union for the latest iteration of its subretinal implant for patients blinded by retinitis pigmentosa. The Alpha AMS is the next-generation version of the Alpha IMS, which won CE Mark approval back in July 2013. The Reutlingen, Germany-based company said the new device increases the number of pixels from 1,500 to 1,600, claiming the title for most electrodes of any neuroprosthetic implant. “We are delighted by the news that our latest device has received the CE Mark. We believe that being able to provide physicians access to th...
Source: Mass Device - March 30, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Optical/Ophthalmic Regulatory/Compliance CE Mark Retina Implant AG Source Type: news

Wayne State start-up, RetroSense, doses first patient in phase I/II RP clinical trial
(Wayne State University - Office of the Vice President for Research) A Wayne State University startup company announced today the first successful dosing of a patient in a clinical trial that is a major step forward for patients with vision challenges. RetroSense Therapeutics LLC, a privately held biopharmaceutical company, successfully dosed their first patient in the first clinical trial to evaluate the safety of RST-001. The study is titled 'Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Uniocular Intravitreal RST-001 in Patients with Retinitis Pigmentosa (RP).' (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 23, 2016 Category: Biology Source Type: news

MassDevice.com +3 | The top 3 medtech stories for March 2, 2016
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. Retina Implant drums up $28m Retina Implant said this week that it raised $28.2 million (€26 million) in private equity funding for its Alpha IMS device, which is designed to treat blind patients with retinitis pigmentosa. The round including contributions from new and existing backers, t...
Source: Mass Device - March 2, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 3 Source Type: news

Retina Implant drums up $28m
Retina Implant said this week that it raised $28.2 million (€26 million) in private equity funding for its Alpha IMS device, which is designed to treat blind patients with retinitis pigmentosa. The round including contributions from new and existing backers, the Reutlingen, Germany-based company said. The proceeds are earmarked for new clinical centers and winning reimbursement in more markets for the Alpha IMS subretinal microchip. “This re-investment is incredibly important to us as it solidifies our investors’ belief in our vision. This continued commitment will allow us to make great leaps fo...
Source: Mass Device - March 2, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Optical/Ophthalmic Alcon Retina Implant AG WaveLight Laser Technologies Source Type: news

Pixium Vision touts 1st-in-human for Iris II retinal implant
French retinal implant maker Pixium Vision today announced the 1st implantation and successful activation of its Iris II epi-retinal implant designed for patients with vision loss as a result of retinitis pigmentosa. The Iris system is comprised of a retinal implant and a pair of camera-mounted glasses connected to a “pocket computer.” The computer processes images captured by the glasses and transmits the data into a signal that’s transferred back and projected onto the intraocular implant, where it stimulates the optic nerve and generates images that the brain learns to interpret as visual signals. &ldq...
Source: Mass Device - February 24, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Pixium Vision Source Type: news